These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Boyle MP; Bell SC; Konstan MW; McColley SA; Rowe SM; Rietschel E; Huang X; Waltz D; Patel NR; Rodman D; Lancet Respir Med; 2014 Jul; 2(7):527-38. PubMed ID: 24973281 [TBL] [Abstract][Full Text] [Related]
6. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. McNamara JJ; McColley SA; Marigowda G; Liu F; Tian S; Owen CA; Stiles D; Li C; Waltz D; Wang LT; Sawicki GS Lancet Respir Med; 2019 Apr; 7(4):325-335. PubMed ID: 30686767 [TBL] [Abstract][Full Text] [Related]
7. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis. Southern KW; Patel S; Sinha IP; Nevitt SJ Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364 [TBL] [Abstract][Full Text] [Related]
8. Long-term safety of lumacaftor-ivacaftor in children aged 2-5 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a multicentre, phase 3, open-label, extension study. Hoppe JE; Chilvers M; Ratjen F; McNamara JJ; Owen CA; Tian S; Zahigian R; Cornell AG; McColley SA Lancet Respir Med; 2021 Sep; 9(9):977-988. PubMed ID: 33965000 [TBL] [Abstract][Full Text] [Related]
9. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor. Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713 [TBL] [Abstract][Full Text] [Related]
10. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Konstan MW; McKone EF; Moss RB; Marigowda G; Tian S; Waltz D; Huang X; Lubarsky B; Rubin J; Millar SJ; Pasta DJ; Mayer-Hamblett N; Goss CH; Morgan W; Sawicki GS Lancet Respir Med; 2017 Feb; 5(2):107-118. PubMed ID: 28011037 [TBL] [Abstract][Full Text] [Related]
11. Lumacaftor/ivacaftor improves liver cholesterol metabolism but does not influence hypocholesterolemia in patients with cystic fibrosis. Gelzo M; Iacotucci P; Caputo M; Cernera G; Comegna M; Carnovale V; Corso G; Castaldo G J Cyst Fibros; 2021 Jan; 20(1):e1-e6. PubMed ID: 32586737 [TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study. Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285 [TBL] [Abstract][Full Text] [Related]
14. Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor. Rubin JL; O'Callaghan L; Pelligra C; Konstan MW; Ward A; Ishak JK; Chandler C; Liou TG Ther Adv Respir Dis; 2019; 13():1753466618820186. PubMed ID: 30803355 [TBL] [Abstract][Full Text] [Related]
15. A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for Rayment JH; Asfour F; Rosenfeld M; Higgins M; Liu L; Mascia M; Paz-Diaz H; Tian S; Zahigian R; McColley SA Am J Respir Crit Care Med; 2022 Nov; 206(10):1239-1247. PubMed ID: 35771568 [No Abstract] [Full Text] [Related]
16. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Kuk K; Taylor-Cousar JL Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827 [TBL] [Abstract][Full Text] [Related]
17. Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. Moheet A; Beisang D; Zhang L; Sagel SD; VanDalfsen JM; Heltshe SL; Frederick C; Mann M; Antos N; Billings J; Rowe SM; Moran A; J Cyst Fibros; 2021 Mar; 20(2):333-338. PubMed ID: 32917547 [TBL] [Abstract][Full Text] [Related]
18. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR. Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP; Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234 [TBL] [Abstract][Full Text] [Related]
19. GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN). van Koningsbruggen-Rietschel S; Conrath K; Fischer R; Sutharsan S; Kempa A; Gleiber W; Schwarz C; Hector A; Van Osselaer N; Pano A; Corveleyn S; Bwirire D; Santermans E; Muller K; Bellaire S; Van de Steen O J Cyst Fibros; 2020 Mar; 19(2):292-298. PubMed ID: 31594690 [TBL] [Abstract][Full Text] [Related]
20. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Milla CE; Ratjen F; Marigowda G; Liu F; Waltz D; Rosenfeld M; Am J Respir Crit Care Med; 2017 Apr; 195(7):912-920. PubMed ID: 27805836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]